Hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and PD-1 inhibitors for advanced hepatocellular carcinoma: A meta-analysis and trial sequential analysis
GastroenterologiaSobre o estudo
- Desenho
- Metanálise
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
- Publicado em
- 6 jan 2025
- Citações
- 4
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and PD-1 inhibitors for advanced hepatocellular carcinoma: A meta-analysis and trial sequential analysis
Jiahui Yu, Yong Li, Jinxin Yu, Yuting Yang, Yimiao Chen, Pengsheng Yi
Descritores MeSH
- Liver Neoplasms
- Phenylurea Compounds
- Quinolines
- Antineoplastic Combined Chemotherapy Protocols
- Immune Checkpoint Inhibitors
- Carcinoma, Hepatocellular
- Programmed Cell Death 1 Receptor
- Hepatic Artery
- Humans
- Infusions, Intra-Arterial
Veja também
Estudos relacionados
- Lenvatinib Versus Bevacizumab in Combination With Anti-PD-1/PD-L1 Therapy for uHCC: A Meta-Analysis of East Asian Studies
- Efficacy and safety of hepatic artery infusion chemotherapy conjunction with tyrosine kinase inhibitors and programmed death-1 inhibitors for unresectable/advanced hepatocellular carcinoma: a meta-analysis
- Terapêutica combinada com anticorpo anti-PD-1, radioterapia e inibidor da tirosina quinase para carcinoma hepatocelular ectópico primário irressecável: relato de caso com perfil genômico e revisão da literatura
- A Network Meta-Analysis Comparing the Efficacy of Lenvatinib, Atezolizumab plus Bevacizumab, and Sorafenib in the Treatment of Unresectable Hepatocellular Carcinoma